ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,361.64
0.05%
Brent Oil
82.345
-0.29%
Bitcoin
61,340.95
0.89%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) News

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RVNC
DateTimeSourceHeadlineSymbolCompany
09/05/202421:33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVNCRevance Therapeutics Inc
09/05/202421:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
09/05/202421:06Business WireRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
09/05/202421:05Business WireRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaNASDAQ:RVNCRevance Therapeutics Inc
02/05/202421:05Business WireRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:RVNCRevance Therapeutics Inc
12/04/202413:00Business WireRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingNASDAQ:RVNCRevance Therapeutics Inc
27/03/202420:05Business WireRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RVNCRevance Therapeutics Inc
08/03/202421:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
05/03/202422:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
05/03/202422:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVNCRevance Therapeutics Inc
04/03/202422:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
04/03/202422:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
04/03/202421:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
04/03/202421:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
04/03/202414:25Business WireRevance Announces Pricing of $100.0 Million Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
04/03/202411:39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVNCRevance Therapeutics Inc
04/03/202411:37Business WireRevance Announces Proposed Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
29/02/202421:36Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
28/02/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
28/02/202421:05Business WireRevance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
21/02/202413:01Business WireRevance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024NASDAQ:RVNCRevance Therapeutics Inc
21/02/202413:00Business WireRevance to Participate in Upcoming Investor ConferencesNASDAQ:RVNCRevance Therapeutics Inc
14/02/202420:45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
13/02/202421:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
13/02/202414:39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
06/02/202421:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
02/02/202421:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
02/02/202421:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
02/02/202421:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
02/02/202413:00Business WireRevance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®NASDAQ:RVNCRevance Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RVNC

Your Recent History

LSE
PET
Petrel Resources
LSE
SYME
Supply@me Capital
LSE
GOLD
LSE
BIRD
Blackbird
LSE
GFM
Griffin Mining
LSE
TERN
Tern
LSE
RKH
Rockhopper Exploration
LSE
ITV
Itv
LSE
SCE
Surface Transforms
LSE
SRSP
Sirius Petroleum
LSE
CNR
Condor Gold
LSE
BBSN
Brave Bison
LSE
ALBA
Alba Mineral Resources
LSE
LLOY
Lloyds Banking
LSE
VAST
Vast Resources
LSE
BOO
Boohoo
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved